Castle Biosciences, Inc.
Castle Biosciences, Inc., a leading biotechnology company headquartered in the United States, specialises in innovative diagnostic solutions for skin cancer and other complex diseases. Founded in 2007, the company has made significant strides in the field of personalised medicine, particularly with its flagship products, the DecisionDx® tests, which provide critical insights for melanoma and non-melanoma skin cancers. With a strong presence across the US and expanding operations internationally, Castle Biosciences is recognised for its commitment to improving patient outcomes through advanced genomic testing. The company has achieved notable milestones, including the successful launch of its proprietary tests that help clinicians make informed treatment decisions. As a pioneer in the dermatological diagnostics industry, Castle Biosciences continues to set the standard for precision medicine, solidifying its position as a trusted partner in oncology care.
DitchCarbon Score
How does Castle Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Castle Biosciences, Inc.'s score of 27 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Castle Biosciences, Inc.'s reported carbon emissions
In 2022, Castle Biosciences, Inc. reported total carbon emissions of approximately 755,080 kg CO2e, which includes 24,130 kg CO2e from Scope 1 emissions and 730,950 kg CO2e from Scope 2 emissions (market-based). The previous year, 2021, the company had similar emissions figures, indicating a consistent approach to managing their carbon footprint. Castle Biosciences has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon emissions. The absence of Scope 3 emissions data suggests that the company may not yet be addressing emissions from its value chain, which is a critical area for comprehensive climate action. As a company headquartered in the US, Castle Biosciences is positioned within an industry increasingly focused on sustainability and climate commitments. However, without defined reduction targets or significant achievements in emissions reduction, their climate strategy appears to be in the early stages of development.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 24,130 | 00,000 |
| Scope 2 | 730,950 | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Castle Biosciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
